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A B S T R A C T
Patients with hypertrophic cardiomyopathy classically have preserved systolic function in the setting of
impaired diastolic function and decreased left ventricular end-diastolic volume. However, in a small sub-
population, patients paradoxically develop systolic dysfunction, left ventricular dilatation, and
ventricular wall thinning. This pattern is one that is likened to dilated cardiomyopathy and is known
as end-stage hypertrophic cardiomyopathy or ‘‘burned-out cardiomyopathy.’’ The role of cardiac
magnetic resonance imaging is well deﬁned in narrowing the differential diagnosis of impaired left
ventricular function, including that of hypertrophic cardiomyopathy. However, the importance of
obtaining a family history and obtaining details of diagnosis for both preceding and future generations
cannot be under-estimated. We report a case of end-stage hypertrophic cardiomyopathy that highlights
how important family history can be in making a diagnosis.
<Learning objective: While most cases of burned-out hypertrophic cardiomyopathy occur long after a
patient has been initially seen and subsequently followed by cardiologists for hypertrophic
cardiomyopathy, a small proportion of patients initially present with this entity. This is one such
case, and it highlights the importance of thorough investigation into a patient’s family history.>
 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
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Burned-out hypertrophic cardiomyopathy (BOHCM), while on
the spectrum of hypertrophic cardiomyopathy (HCM), is often
described as a separate entity in its own right. It typically
resembles a pattern of dilated cardiomyopathy, with the major
difference being that it is born of HCM. Usually this diagnosis is a
relatively straightforward one as a cardiologist has generally seen
patients with HCM long before they reach the so-called ‘‘burned-
out phase.’’ We describe a case in which a known family history of
HCM coupled with phenotypic similarity on cardiac magnetic
resonance (CMR) images allowed a diagnosis of BOHCM to be made
without the original diagnosis of HCM. This similarity in
phenotypic expression of HCM has been previously documented
in monozygotic twins [1,2]. To our knowledge, this is the ﬁrst time* Corresponding author at: Clinical Science Institute, School of Medicine, National
University Ireland, Galway, Newcastle Road, Galway, Ireland.
Tel.: +353 876632546; fax: +353 91792002.
E-mail address: george.rahmani@gmail.com (G. Rahmani).
http://dx.doi.org/10.1016/j.jccase.2014.10.010
1878-5409/ 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rightthat phenotypic expression of HCM has been described in ﬁrst-
degree relatives; one relative with a diagnosis of HCM and the
other with a diagnosis of BOHCM.
Case report
A 58-year-old, asymptomatic, man presented for cardiac
screening due to the presence of non-sustained wide complex
tachycardia lasting for 5 beats on routine electrocardiogram
(Fig. 1). His father died suddenly at the age of 28 years. The
patient’s daughter is currently being followed for suspected HCM
with a maximal left ventricular (LV) wall thickness of 26 mm along
the mid-basal anterior septum. The patient denies any history of
alcohol or drug abuse, hypertension, connective tissue disorder,
or human immunodeﬁciency virus. Further review of symptoms
reveals mild exertional dyspnea (New York Heart Association
Class I) with no history of chest pain, syncope, or palpitations.
Other than a body mass index of 31, the physical examination is
unremarkable.
On echocardiogram, there is evidence of LV dysfunction
(ejection fraction 40%) with a thin and akinetic anterior septum.s reserved.
Fig. 1. Initial presenting electrocardiogram with ﬁve beats of non-sustained ventricular tachycardia.
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elevated LV end-diastolic pressure of 19 mmHg. CMR imaging
demonstrated a dilated LV with impaired systolic function
(ejection fraction 42%). There was deﬁnite ventricular wall
thinning (0.9 cm) with LV dilatation along with a large volume
of myocardial scarring (25% of total LV mass). The scar was
transmural in the basal, anterior, mid-anterior, and inferior wall
(Fig. 2). The patient’s daughter had had previous imaging studies
performed as part of her investigations for HCM. The location of
myocardial scar, as demonstrated by CMR, was in a similar pattern
of distribution to that of his daughter’s segments of hypertrophy.
Comparing the myocardial scar pattern in the patient to the
corresponding segments of marked hypertrophy in the patient’sFig. 2.
Comparing cardiac magnetic resonance images of patient and daughter. Note
images and the segments of myocardial hypertrophy in the daughter’s images (
is the GE1 name for a balanced steady-state gradient echo sequence, otherwdaughter, we hypothesized that not only did this patient have
undiagnosed HCM, but that his clinical status had progressed to
that of end-stage HCM or BOHCM. Although the patient was
‘‘asymptomatic,’’ given his non-sustained ventricular tachycardia,
impaired LV function, large myocardial scar burden, and presumed
diagnosis of BOHCM, the patient was offered an implantable
cardioverter deﬁbrillator.
Discussion
HCM is the most common genetic disease of the heart. This
autosomal dominant condition is caused by mutations in genes
encoding sarcomere proteins and affects approximately 1 in the similar pattern of distribution of segments of myocardial scar in the patient’s
please note: ‘FIESTA’ refers to fast imaging employing steady-state acquisition and
ise known as ‘TrueFISP’ [Siemens1] or ‘balanced-FFE’ [Philips1]).
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left ventricular hypertrophy associated with nondilated ventricu-
lar chambers and is generally recognized by maximal LV wall
thickness 15 mm, with wall thickness of 13–14 mm considered
borderline [4]. The average maximal LV wall thickness is 20–22 mm
with marked hypertrophy (30–50 mm) occurring in 5–10% of cases
[3]. Patients with HCM classically have preserved systolic function in
the setting of impaired diastolic function and decreased LV end-
diastolic volume. However, in a small sub-population, patients
paradoxically develop systolic dysfunction, LV dilatation, and
ventricle wall thinning [3]. This dilated-hypokinetic evolution of
HCM resembles the morphologic and functional features of dilated
cardiomyopathy and is often referred to as the end-stage, dilated, or
‘‘burned-out’’ phase of HCM [5].
This ‘‘burned-out’’ phase occurs due to the loss of myocardium
by replacement ﬁbrosis. This is thought to occur as a consequence
of myocardial ischemia caused by disease of the small intramural
myocardial arteries [6]. Other proposed mechanisms include
transmural myocardial infarction and excessive alcohol intake
[7,8]. Genetic factors have also been implicated, with the novel
missense mutation Lys273Glu in the cardiac troponin T gene being
associated with a partial transition to the dilated phase of HCM [9].
The incidence of progression from classical HCM to BOHCM is in
the region of 5 per 1000 patient years, with a prevalence of 5% at
ﬁrst diagnosis of HCM [5,10]. This progression is generally slow,
unpredictable, and associated with atrial ﬁbrillation [11,12]. It has
also been associated with younger age and greater wall thickness
at initial diagnosis of HCM, as well as a family history of HCM.
BOHCM is an important diagnosis to make as patients will either
die, or undergo heart transplantation within an average of 5 years
from the time this entity is identiﬁed [5]. Mortality rates are
quoted to be as high as 11% per year, further emphasizing the poor
prognosis attached to this condition [11].
The evolution of CMR imaging allows identiﬁcation and
quantiﬁcation of previously unrecognized myocardial abnormali-
ties and its potential is being realized beyond assessing global LV
function. In some cases CMR imaging is capable of identifying
segments of hypertrophy not readily recognized by echocardiog-
raphy. Using late gadolinium hyperenhancement, one can also
yield evidence of myocardial scarring, which distinguishes HCM
from ‘‘athlete’s heart’’ [3]. It is the arena of risk stratiﬁcation for
sudden cardiac death wherein lies another potential use for CMR
imaging. Although the presence of total scar as detected by CMR
imaging has been associated with increased rates of cardiac events,
its discriminant ability as a single risk factor has yet to be
established [13].
In the case of the above patient, CMR imaging proved useful
when the imaging studies were used to compare and contrast with
similar imaging studies in a ﬁrst-degree relative, namely the
patient’s daughter. The area and pattern of distribution of the
patient’s dilated wall was strikingly similar to that of his daughter’s
segments of hypertrophy.
In conclusion, while most cases of BOHCM occur long after a
patient has been initially seen and subsequently followed by
cardiologists for HCM, a small proportion of patients initially
present with this entity. This is one such case, and it highlights theimportance of thorough investigation into a patient’s family
history. On establishing a family history of HCM, the patient’s CMR
images were able to be compared with those of a ﬁrst-degree
relative and this proved to be an extremely fruitful exercise,
without which, diagnosing BOHCM would have been much more
difﬁcult.
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